JP2015505818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505818A5 JP2015505818A5 JP2014541396A JP2014541396A JP2015505818A5 JP 2015505818 A5 JP2015505818 A5 JP 2015505818A5 JP 2014541396 A JP2014541396 A JP 2014541396A JP 2014541396 A JP2014541396 A JP 2014541396A JP 2015505818 A5 JP2015505818 A5 JP 2015505818A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- fgfr1
- therapeutic agent
- agent according
- ecd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559259P | 2011-11-14 | 2011-11-14 | |
| US61/559,259 | 2011-11-14 | ||
| US201261616761P | 2012-03-28 | 2012-03-28 | |
| US61/616,761 | 2012-03-28 | ||
| PCT/US2012/064772 WO2013074492A1 (en) | 2011-11-14 | 2012-11-13 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091502A Division JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505818A JP2015505818A (ja) | 2015-02-26 |
| JP2015505818A5 true JP2015505818A5 (https=) | 2017-01-05 |
Family
ID=48430074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541396A Pending JP2015505818A (ja) | 2011-11-14 | 2012-11-13 | 癌を治療する方法 |
| JP2017091502A Active JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091502A Active JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20130136740A1 (https=) |
| EP (1) | EP2780033B1 (https=) |
| JP (2) | JP2015505818A (https=) |
| CN (2) | CN107823630A (https=) |
| AU (1) | AU2012318247B2 (https=) |
| CA (1) | CA2855818A1 (https=) |
| HK (2) | HK1201462A1 (https=) |
| TW (1) | TW201326201A (https=) |
| WO (1) | WO2013074492A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| CN102171343B (zh) | 2008-08-04 | 2017-07-14 | 戊瑞治疗有限公司 | Fgfr细胞外结构域酸性区突变蛋白 |
| AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| JP2015505818A (ja) | 2011-11-14 | 2015-02-26 | ファイブ プライム セラピューティックス インコーポレイテッド | 癌を治療する方法 |
| TWI718086B (zh) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| AU2014259956A1 (en) * | 2013-05-01 | 2015-11-12 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| TWI728975B (zh) * | 2015-05-12 | 2021-06-01 | 英屬維爾京群島商遠東超級實驗室有限公司 | 鑒定對腫瘤具有直接抑制作用的干擾素的方法及其用途 |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| CN107794293A (zh) * | 2016-08-31 | 2018-03-13 | 安诺优达基因科技(北京)有限公司 | 一种基因捕获试剂盒 |
| CN109609640A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院上海高等研究院 | Etv4的用途 |
| US20220267735A1 (en) * | 2019-08-05 | 2022-08-25 | Genex Health Co., Ltd | Method for culturing primary cells from solid tumor of lung cancer and primary tumor cells from pleural effusion of lung cancer and auxiliary reagents |
| CN111735950B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Fgf18和ca125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN111912987B (zh) * | 2020-08-25 | 2023-07-21 | 北京信诺卫康科技有限公司 | Fgf18和he4联合用作早期卵巢癌生物标志物以及试剂盒 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486462A (en) | 1984-11-23 | 1996-01-23 | The Regents Of The University Of California | Differentiative expression modules |
| GB9001466D0 (en) | 1990-01-23 | 1990-03-21 | Erba Carlo Spa | Extracellular form of the human fibroblast growth factor receptor |
| US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| JP3039802B2 (ja) | 1989-07-06 | 2000-05-08 | ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア | 繊維芽細胞成長因子のための受容体 |
| US5750371A (en) | 1990-04-27 | 1998-05-12 | Takeda Chemical Industries Ltd | Water-soluble mutein of FGF receptor, DNA and production thereof |
| CA2086425C (en) | 1990-07-06 | 2006-01-17 | Craig A. Dionne | Fibroblast growth factor receptors |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| US5229501A (en) | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
| IL100219A0 (en) | 1991-12-02 | 1992-09-06 | Yeda Res & Dev | Variable region within fibroblast growth factor receptors that confers ligand specificity |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US6517872B1 (en) | 1995-06-12 | 2003-02-11 | Yeda Research And Development Co., Ltd. | FGFR3 as a marker for mesenchymal skeletal progenitor cells |
| WO1997048813A2 (en) | 1996-06-18 | 1997-12-24 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fibroblast growth factor receptor activating gene 1 (frag1). fgfr2-frag1 fusions |
| DE19802377A1 (de) | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
| US6656728B1 (en) | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| WO2003038054A2 (en) | 2001-10-31 | 2003-05-08 | New York University | Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds |
| CA2492267C (en) | 2002-07-15 | 2013-09-10 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| CA2550245A1 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| JP2008506366A (ja) | 2004-05-14 | 2008-03-06 | レセプター バイオロジックス インコーポレイテッド | 細胞表面受容体アイソフォームならびにその同定および使用方法 |
| US7872016B2 (en) | 2004-05-25 | 2011-01-18 | Yale University | Method for treating skeletal disorders resulting from FGFR malfunction |
| EP1841874B1 (en) | 2005-01-27 | 2010-01-06 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| WO2007059574A1 (en) | 2005-11-23 | 2007-05-31 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| EP1989230B1 (en) | 2006-02-10 | 2016-06-01 | Genentech, Inc. | Anti-fgf19 antibodies and methods using same |
| CA2651755A1 (en) | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
| CL2007003411A1 (es) | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
| EP2125032A4 (en) | 2007-02-20 | 2011-02-23 | Mayo Foundation | CANCER TREATMENT WITH VIRAL NUCLEIC ACID |
| KR20100015883A (ko) | 2007-03-23 | 2010-02-12 | 더 트랜스내셔날 게노믹스 리서치 인스티튜트 | 자궁내막암 및 전암을 진단，분류 및 치료하는 방법 |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| UY31478A1 (es) | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
| CA2720888A1 (en) | 2008-04-29 | 2009-11-05 | Novartis Ag | Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods |
| CN102171343B (zh) | 2008-08-04 | 2017-07-14 | 戊瑞治疗有限公司 | Fgfr细胞外结构域酸性区突变蛋白 |
| WO2011034940A1 (en) | 2009-09-15 | 2011-03-24 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr4 extracellular domains |
| AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| EP2512501A4 (en) | 2009-12-17 | 2014-01-01 | Five Prime Therapeutics Inc | METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP5945277B2 (ja) | 2010-11-15 | 2016-07-05 | ファイブ プライム セラピューティックス インコーポレイテッド | Ｆｇｆｒ１細胞外ドメイン併用療法 |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| IT1404531B1 (it) | 2011-02-24 | 2013-11-22 | Sisvel Technology Srl | Procedimento e sistema di localizzazione indoor per terminali mobili in una rete di telecomunicazione mobile cellulare e relativo terminale mobile. |
| WO2012125812A1 (en) | 2011-03-17 | 2012-09-20 | Novartis Ag | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects |
| WO2012177481A2 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| JP2015505818A (ja) | 2011-11-14 | 2015-02-26 | ファイブ プライム セラピューティックス インコーポレイテッド | 癌を治療する方法 |
| AU2014259956A1 (en) | 2013-05-01 | 2015-11-12 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
-
2012
- 2012-11-13 JP JP2014541396A patent/JP2015505818A/ja active Pending
- 2012-11-13 TW TW101142331A patent/TW201326201A/zh unknown
- 2012-11-13 CN CN201711171931.8A patent/CN107823630A/zh active Pending
- 2012-11-13 WO PCT/US2012/064772 patent/WO2013074492A1/en not_active Ceased
- 2012-11-13 AU AU2012318247A patent/AU2012318247B2/en active Active
- 2012-11-13 HK HK15102035.6A patent/HK1201462A1/xx unknown
- 2012-11-13 EP EP12849489.5A patent/EP2780033B1/en active Active
- 2012-11-13 HK HK15102726.0A patent/HK1202240A1/xx unknown
- 2012-11-13 US US13/675,255 patent/US20130136740A1/en not_active Abandoned
- 2012-11-13 CN CN201280066268.4A patent/CN104168915A/zh active Pending
- 2012-11-13 CA CA2855818A patent/CA2855818A1/en not_active Abandoned
- 2012-11-13 US US14/357,336 patent/US10016484B2/en active Active
-
2017
- 2017-05-02 JP JP2017091502A patent/JP6578318B2/ja active Active
-
2018
- 2018-06-08 US US16/003,590 patent/US10537611B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505818A5 (https=) | ||
| Wang et al. | Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers | |
| Tan et al. | PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA | |
| Yau | Precision treatment in colorectal cancer: Now and the future | |
| Durães et al. | Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? | |
| Kim et al. | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma | |
| Smith et al. | Strategies for modern biomarker and drug development in oncology | |
| Bamias et al. | A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer | |
| Kim et al. | Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion | |
| Yu et al. | VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer | |
| US20170198353A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
| Stewart et al. | New therapies for clear cell ovarian carcinoma | |
| Westin et al. | Personalized therapy in endometrial cancer: challenges and opportunities | |
| JP2012529895A (ja) | 抗ｅｇｆｒ抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法 | |
| Capdevila et al. | Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets | |
| JP2016526016A5 (https=) | ||
| Chiang et al. | Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas | |
| CN115176008B (zh) | 用于抑制FoxP3表达的修饰反义寡核苷酸 | |
| RU2015150233A (ru) | Способы лечения злокачественной опухоли | |
| US20140030257A1 (en) | Agtr1 as a marker for bevacizumab combination therapies | |
| Hill et al. | Targeted therapies in non-small-cell lung cancer | |
| Wang et al. | FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma | |
| Choi et al. | Mutational and expressional analysis of ERBB 3 gene in common solid cancers | |
| Kusumaningrum et al. | A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance | |
| Yuan et al. | CircPIK3C3 inhibits hepatocellular carcinoma progression and lenvatinib resistance by suppressing the Wnt/β-catenin pathway via the miR-452-5p/SOX15 axis |